Brian Singerman

Partner Emeritus at GPx

Reviewed Updated Mar 27, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Founders Fund Partner Emeritus (2008-2024) and co-founder of $500M fund GPx with Peter Thiel. Invests in frontier tech with concentration in biotech (27%) and defense (23%) — sectors most VCs avoid. His sector-agnostic claim understates revealed preference for regulated, capital-intensive domains requiring deep technical expertise; portfolio includes Anduril, Stemcentrx, and SpaceX.

Location San Francisco, CA
Check Size $1M-$300M
Last Verified Investment Anduril Industries (Series E) — 2022

Background

Brian Singerman is an American venture capitalist and partner emeritus at Founders Fund, the San Francisco-based venture capital firm founded by Peter Thiel 12. He graduated from Stanford University in 1999 with a B.S. in Computer Science 1.

After Stanford, Singerman joined There, Inc., a virtual-world online startup, as a software engineer 13. In 2004, he moved to Google, where he spent four years as an engineer and executive 13. At Google, he founded iGoogle, the personalized web portal product 13. During his time at Google, Singerman launched his first investment vehicle, a $1 million fund called the XGYC Fund (short for “ex-Google, Y Combinator”), which invested in early Y Combinator companies starting around 2007 13.

In 2008, Singerman joined Founders Fund as a principal, becoming a partner in 2011 34. Over a 16-year tenure, he became one of the firm’s most prolific investors, generating some of Founders Fund’s largest returns 25. He was ranked #5 on the 2017 Forbes Midas List, up from #36 the prior year, driven largely by the Stemcentrx exit 6.

On December 3, 2024, Singerman announced his transition from general partner to partner emeritus at Founders Fund, stating he would continue as an investor and strategic advisor while seeking better work-life balance 25. In July 2025, he and Lee Linden (co-founder of Quiet Capital) announced they were raising over $500 million for a new fund called GPx, with Peter Thiel expected to contribute a significant portion of the capital 7. GPx will invest approximately 20% of its capital into funds managed by emerging seed-stage VCs, with the remaining 80% going toward co-leading Series B rounds in those managers’ breakout portfolio companies 78.

Stated Thesis

(Self-reported: These represent what Singerman says publicly about his investing approach. See Inferred Thesis for analysis of actual investment behavior.)

Singerman describes himself as sector-agnostic and conviction-driven. On the 20VC podcast, he stated: “My expertise is in the founders, the execution of founders, the strategy and the moats that these companies have. And I think that that just scales across all sectors” 9.

He has publicly described venture capital as purely about upside maximization: “Venture capital to me is purely a game of upside maximization. And while this may get me in trouble, I actually don’t. Downside minimization is completely unimportant to me” 9.

Singerman has said he does not look for consensus validation from other VCs: “The way you make money in venture capital is by backing the truck in and being correct. I’m not looking for validation from other VC firms at all. I’m not interested in marking up a portfolio of companies. I’m interested in these companies being very large and having impact” 9.

He has emphasized the importance of early-stage relationships: “Entrepreneurs love when an investor is willing to take an early bet on them and be right” 9.

On founder selection, Singerman has said: “When you find a phenomenal founder, you back them regardless of what they are doing” 10.

Inferred Thesis

Based on 22 verified investments listed below, Singerman’s actual investment behavior reveals a concentrated, high-conviction approach focused on frontier technology companies operating in large, often regulated markets.

Sector distribution (22 verified investments): 6 biotech/life sciences (27%), 5 defense/government technology (23%), 4 AI/data infrastructure (18%), 3 fintech (14%), 2 consumer internet (9%), 2 other/hard-tech (9%).

Stage distribution: Singerman invests across the full spectrum from seed to growth. His highest-profile investments (Anduril, Stemcentrx, SpaceX) involved multiple rounds of follow-on, with Founders Fund writing checks as large as $400M into Anduril across rounds 11. He has also led seed rounds, such as Anduril’s $17.5M seed in 2017 12.

Founder profile patterns: Singerman gravitates toward technical founders building in deeply complex domains. He has explicitly compared Palmer Luckey to Elon Musk as a technologist-visionary 10. His portfolio skews toward founders with deep domain expertise in regulated or hard-tech industries (cancer therapeutics, defense systems, rocket engineering).

Co-investor patterns: As a Founders Fund partner, Singerman frequently co-invested with the firm’s other partners, particularly Peter Thiel. Notable co-investors across his portfolio include Sequoia Capital (Airbnb, Scale AI), Andreessen Horowitz (Anduril), and General Catalyst (Affirm).

Notable gaps between stated and actual thesis: While Singerman describes himself as sector-agnostic, his portfolio reveals strong concentrations in biotech (27%) and defense tech (23%) – sectors that most VCs avoid entirely. His “agnostic” framing understates a clear revealed preference for regulated, capital-intensive, technically complex domains where most venture firms lack the expertise or risk appetite to invest.

Portfolio

Company Year Stage Source
Stemcentrx 2013 Series B 1314
Airbnb ~2013 Growth 15
Oculus VR ~2013 Early 13
Oscar Health 2014 Early 13
Wish 2014 Growth 13
Affirm 2015 Early 13
Asana ~2015 Growth 13
Postmates ~2015 Growth 13
OpenAI 2016 Early 15
Anduril Industries 2017 Seed 1012
Freenome ~2017 Early 15
Scale AI 2018 Early 15
Applied Intuition 2018 Early 15
Tempus ~2018 Growth 15
Cloud9 ~2018 Early 3
Emerald Therapeutics ~2016 Early 3
Solugen ~2019 Early 3
Long-Term Stock Exchange ~2018 Early 3
Forward ~2017 Early 3
Modern Health ~2019 Early 3
Ginkgo Bioworks ~2015 Early 15
SpaceX ~2008 Growth 25

This table represents a partial view of Singerman’s portfolio. Analysis sources estimate approximately 65 active investments total 15. Many investments were made through Founders Fund vehicles and individual deal attribution is not always publicly disclosed. Years marked with ~ are approximate, based on founding year or earliest reported connection.

In Their Own Words

On the Stemcentrx due diligence process, Singerman said: “We weren’t space experts and wouldn’t have done SpaceX if Elon wasn’t running it. This was similar for us.” He also noted: “Scientists are usually very conservative, but we knew that Stemcentrx really had something when these oncologists told us, ‘Well, it won’t obviously not work.’” 14

On how Founders Fund operates internally: “We’ve tried to have Monday partner meetings…it just doesn’t work for us” 9.

On the investment decision process: “Somebody who sees the deal, somebody who brings in the deal has to have enough conviction to at least get the rest of the team to take a look” 9.

On business fundamentals: “So especially at the later stage, even if, let’s say, somebody like me has a great gut feel, if the business side doesn’t also check out, we’re probably not making that investment” 9.

On the importance of both technical and business talent: “You need just as good business people on your team as you do technology people in order to win” 10.

On founder relationships: “The only way to get ahead of growth is to invest in a relationship with the founder” 10.

On his core job: “For my job at this fund is to generate massive returns. And for our fund, you simply have to invest in the world’s most important companies in order to generate those returns” 9.

What Founders Say

No independently sourced founder testimonials found. Singerman is widely described as a board director at Affirm, Oscar Health, Postmates, Cloud9, Emerald Therapeutics, Solugen, and Long-Term Stock Exchange, and as a board observer at Airbnb, Forward, Modern Health, and Wish 3, suggesting active post-investment engagement across his portfolio. However, no direct founder quotes about working with Singerman could be independently verified at this time.

Connections

  • Board director, Affirm — alongside Max Levchin (CEO & Co-Founder) 3
  • Board director, Oscar Health — alongside Mario Schlosser (Co-Founder & CEO) 3
  • Board director, Postmates — prior to Uber acquisition in 2020 3
  • Board director, Stemcentrx — prior to AbbVie acquisition in 2016 14
  • Board director, Solugen — current 3
  • Board director, Long-Term Stock Exchange — alongside Eric Ries (CEO & Founder) 3
  • Board observer, Airbnb1
  • Board observer, Anduril Industries — alongside Palmer Luckey (CEO & Founder) 3
  • Board observer, Modern Health — current 3
  • Former Google engineer (2004-2008) — founded iGoogle product 13
  • Co-founder, GPx — with Lee Linden (ex-Quiet Capital), Peter Thiel as major LP 78
  • Frequent co-investor with Peter Thiel — via Founders Fund across SpaceX, Anduril, and others 25

Sources


  1. Wikipedia, “Brian Singerman,” accessed March 2026. https://en.wikipedia.org/wiki/Brian_Singerman

  2. CNBC, “Peter Thiel’s Founders Fund loses early partner Brian Singerman,” December 3, 2024, accessed March 2026. https://www.cnbc.com/2024/12/03/peter-thiels-founders-fund-loses-early-partner-brian-singerman.html

  3. TechAviv, “Brian Singerman” profile, accessed March 2026. https://www.techaviv.com/people/brian-singerman

  4. Signal by NFX, “Brian Singerman’s Investing Profile,” accessed March 2026. https://signal.nfx.com/investors/brian-singerman

  5. TechCrunch, “Brian Singerman to take a step back from Founders Fund,” December 3, 2024, accessed March 2026. https://techcrunch.com/2024/12/03/brian-singerman-to-take-a-step-back-from-founders-fund/

  6. Forbes Midas List 2017, reported via GlobeNewsWire, April 19, 2017, accessed March 2026. https://www.globenewswire.com/news-release/2017/04/19/962354/6948/en/The-2017-Forbes-Midas-List-of-the-World-s-Top-Venture-Capitalists-to-Ring-The-Nasdaq-Stock-Market-Opening-Bell.html

  7. TechCrunch, “Brian Singerman is raising over $500M for a new fund with a twist on the VC model,” July 14, 2025, accessed March 2026. https://techcrunch.com/2025/07/14/brian-singermans-new-fund-has-a-twist-and-peter-thiel-as-a-big-backer/

  8. VCWire, “Brian Singerman and Lee Linden Raising $500M For First GPx Fund,” July 15, 2025, accessed March 2026. https://vcwire.tech/2025/07/15/brian-singerman-and-lee-linden-raising-500m-for-first-gpx-fund/

  9. 20VC podcast (Deciphr transcript), “Founders Fund’s Brian Singerman on Why VC Is About Upside Maximisation Not Downside Minimisation,” accessed March 2026. https://www.deciphr.ai/podcast/20vc-founders-funds-brian-singerman-on-why-vc-is-about-upside-maximisation-not-downside-minimisation-why-there-is-no-right-way-to-do-venture-and-why-they-do-not-have-monday-morning-partner-meetings-at-founders-fund

  10. Podcast Notes, “20VC: The Anduril Memo: Founders Fund’s Brian Singerman on What Makes Palmer Luckey One of the Greatest Innovators in History,” accessed March 2026. https://podcastnotes.org/20vc-with-harry-stebbings/the-anduril-memo-founders-funds-brian-singerman-on-what-makes-palmer-luckey-one-of-the-greatest-innovators-in-history-why-it-is-bs-the-dod-do-not-want-to-work-with-silicon-valley-why-in-venture/

  11. 20VC podcast episode page, “Founders Fund’s Brian Singerman on Writing a $400M Check Into Anduril Across Rounds,” accessed March 2026. https://www.thetwentyminutevc.com/brian-singerman

  12. Yahoo Finance / Reuters, “Oculus founder Palmer Luckey’s defense startup rounded up high-profile investors to build a high-tech border wall,” accessed March 2026. https://finance.yahoo.com/news/oculus-founder-palmer-luckey-apos-165440381.html

  13. BioSpace, “AbbVie Pays $5.8 Billion+ for Bay Area’s Stemcentrx, Which Has Ties to PayPal and SpaceX Investors,” April 2016, accessed March 2026. https://www.biospace.com/abbvie-pays-5-8-billion-for-bay-area-s-stemcentrx-which-has-ties-to-b-paypal-b-and-b-spacex-b-investors

  14. Fortune, “AbbVie Buying Cancer Drug Startup Stemcentrx for $10.2 Billion,” April 28, 2016, accessed March 2026. https://fortune.com/2016/04/28/abbvie-stemcentx/

  15. DigitDAI, “Brian Singerman: Founders Fund’s AI & Biotech Bets,” November 27, 2025, accessed March 2026. https://digidai.github.io/2025/11/27/brian-singerman-founders-fund-ai-biotech-investment-deep-analysis/